Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The abnormal blood vessel growth found in wet AMD is partially caused by the presence of VEGF (vascular endothelial growth ...

The abnormal blood vessel growth found in wet AMD is partially caused by the presence of VEGF (vascular endothelial growth factor), a signaling molecule ... Eylea or Eylea HD (aflibercept) Beovu ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from launching its aflibercept biosimilar, Amgen announced on its ...

The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...